In a Phase I/II trial, 8 Japanese patients with SS positive for HLA-A*02:01 or HLA-A*02:06 and NY-ESO-1 tumour expression received cyclophosphamide 750 mg/m2 on days −3 and −2 (induction period) followed by an infusion of a split dose of a cell suspension of 5 × 109 (±30%) autologous T lymphocytes expressing NY-ESO-1 antigen-specific TCR gene and siRNA to inhibit the expression of endogenous TCR (product code: TBI-1301) on days 0 and 1. Here, HLA-A is linked to neoplasm.